Camel Ventures

Canaan Partners is a San Francisco and New York-based venture capital firm with more than three decades of operating history, founded in 1987 and focused on early-stage and growth investments in healthcare and life sciences, enterprise technology, and financial technology. The firm has managed fourteen funds over its history and has invested in more than 400 companies, generating significant returns across multiple technology cycles including the internet boom, the SaaS transition, the healthcare technology wave, and the current AI era. Canaan's healthcare and biotech franchise has produced a series of clinical-stage and commercial-stage biopharmaceutical exits and IPOs, while its technology practice has backed companies in networking, communications, and enterprise SaaS. Acacia Communications, the optical networking company backed by Canaan, completed a Nasdaq IPO in 2016 and was acquired by Cisco for $4.5 billion in 2021. LendingClub, the peer-to-peer lending platform, completed a NYSE IPO in 2014 with Canaan as an early investor. EQRx is a clinical-stage pharmaceutical company backed by Canaan seeking to develop and commercialize innovative medicines at lower prices. Aclaris Therapeutics is a dermatology-focused biopharmaceutical company. The original directory lists Acacia, Aclaris, CytRx, and EQRx as portfolio companies, reflecting Canaan's biotech focus. Beyond these original investments, the broader portfolio includes enterprise software, healthtech, and financial technology companies across multiple fund vintages.